SLC5A2 and heart failure: While SGLT2 inhibitors improved cardiovascular and renal outcomes, reduced hospitalizations for heart failure, and provided potential weight and blood pressure benefits, there is an increased risk of genital infections, ketoacidosis in patients with diabetes, and, rarely, lower limb amputations [33].